LT3283067T - Trumpo poveikio fenilalkilamino kalcio kanalų blokatoriaus gerai vandenyje tipstančios druskos ir jų panaudojimas - Google Patents

Trumpo poveikio fenilalkilamino kalcio kanalų blokatoriaus gerai vandenyje tipstančios druskos ir jų panaudojimas

Info

Publication number
LT3283067T
LT3283067T LTEP16779363.7T LT16779363T LT3283067T LT 3283067 T LT3283067 T LT 3283067T LT 16779363 T LT16779363 T LT 16779363T LT 3283067 T LT3283067 T LT 3283067T
Authority
LT
Lithuania
Prior art keywords
phenylkylamine
short
calcium channel
channel blocker
based salts
Prior art date
Application number
LTEP16779363.7T
Other languages
English (en)
Inventor
Martin P. Maguire
Original Assignee
Milestone Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57125495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3283067(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Milestone Pharmaceuticals Inc. filed Critical Milestone Pharmaceuticals Inc.
Publication of LT3283067T publication Critical patent/LT3283067T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEP16779363.7T 2015-04-14 2016-04-13 Trumpo poveikio fenilalkilamino kalcio kanalų blokatoriaus gerai vandenyje tipstančios druskos ir jų panaudojimas LT3283067T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147427P 2015-04-14 2015-04-14
PCT/CA2016/050425 WO2016165014A1 (en) 2015-04-14 2016-04-13 Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof

Publications (1)

Publication Number Publication Date
LT3283067T true LT3283067T (lt) 2020-06-25

Family

ID=57125495

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16779363.7T LT3283067T (lt) 2015-04-14 2016-04-13 Trumpo poveikio fenilalkilamino kalcio kanalų blokatoriaus gerai vandenyje tipstančios druskos ir jų panaudojimas

Country Status (28)

Country Link
US (13) US10117848B2 (lt)
EP (3) EP4428119A3 (lt)
JP (1) JP6785792B2 (lt)
KR (3) KR20250057109A (lt)
CN (2) CN113694019A (lt)
AU (1) AU2016249030B2 (lt)
BR (1) BR112017021620B1 (lt)
CA (2) CA2982622C (lt)
CY (1) CY1122931T1 (lt)
DK (1) DK3283067T3 (lt)
ES (2) ES2778673T3 (lt)
HR (1) HRP20200444T1 (lt)
HU (1) HUE049570T2 (lt)
IL (1) IL254889B (lt)
LT (1) LT3283067T (lt)
MA (2) MA46679B1 (lt)
MD (1) MD3283067T2 (lt)
ME (1) ME03679B (lt)
MX (1) MX372659B (lt)
PL (2) PL3283067T3 (lt)
PT (2) PT3689344T (lt)
RS (1) RS60154B1 (lt)
RU (1) RU2731918C2 (lt)
SI (1) SI3283067T1 (lt)
SM (1) SMT202000149T1 (lt)
UA (1) UA121330C2 (lt)
WO (1) WO2016165014A1 (lt)
ZA (2) ZA201706648B (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119137A1 (en) 2021-07-15 2023-01-18 Milestone Pharmaceuticals Inc. Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
KR20240147942A (ko) 2023-03-31 2024-10-10 주식회사 엘지화학 오토택신 저해제로서의 신규한 벤즈이미다졸론 유도체 화합물
WO2025215083A1 (en) 2024-04-10 2025-10-16 Dipharma Francis S.R.L. Method for preparing a drug used for paroxysmal supraventricular tachycardia
WO2025229679A1 (en) * 2024-04-30 2025-11-06 Cipla Limited Process for synthesis of etripamil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605074D0 (en) * 1996-03-11 1996-05-08 Chiroscience Ltd Dosage forms and uses
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US6831663B2 (en) * 2001-05-24 2004-12-14 Microsoft Corporation System and process for automatically explaining probabilistic predictions
US20050191245A1 (en) 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
WO2008019106A1 (en) * 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
CA2693627C (en) 2007-06-20 2016-01-12 Milestone Pharmaceuticals Inc. Short acting phenylalkylamine calcium channel blockers and uses thereof
US20090318413A1 (en) 2008-06-18 2009-12-24 Universite Victor Segalen Bordeaux 2 Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma
CA2835771C (en) * 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Also Published As

Publication number Publication date
IL254889B (en) 2021-07-29
ME03679B (me) 2020-10-20
ES2986137T3 (es) 2024-11-08
US20230414553A1 (en) 2023-12-28
US20250332137A1 (en) 2025-10-30
CY1122931T1 (el) 2021-10-29
EP3283067A4 (en) 2018-12-05
RU2017134553A (ru) 2019-04-05
AU2016249030B2 (en) 2020-08-27
US20230157990A1 (en) 2023-05-25
ES2778673T3 (es) 2020-08-11
KR20250057109A (ko) 2025-04-28
KR20180019508A (ko) 2018-02-26
BR112017021620A2 (pt) 2018-07-03
EP3283067A1 (en) 2018-02-21
CA2982622A1 (en) 2016-10-20
CA3203288A1 (en) 2016-10-20
US20190022048A1 (en) 2019-01-24
HRP20200444T1 (hr) 2020-06-12
US20220040139A1 (en) 2022-02-10
KR102653347B1 (ko) 2024-04-02
NZ736249A (en) 2024-07-05
HUE049570T2 (hu) 2020-10-28
US20200368195A1 (en) 2020-11-26
UA121330C2 (uk) 2020-05-12
US20200121631A1 (en) 2020-04-23
ZA201807495B (en) 2024-04-24
MA46679A (fr) 2018-02-21
CN107613970B (zh) 2021-10-19
PL3689344T3 (pl) 2024-11-04
US20210205258A1 (en) 2021-07-08
HK1249417A1 (en) 2018-11-02
MA52480A (fr) 2022-03-09
KR20240044546A (ko) 2024-04-04
JP6785792B2 (ja) 2020-11-18
SMT202000149T1 (it) 2020-05-08
WO2016165014A1 (en) 2016-10-20
US20250090488A1 (en) 2025-03-20
PT3283067T (pt) 2020-03-31
MX372659B (es) 2020-03-26
EP3283067B1 (en) 2020-01-01
MX2017013355A (es) 2019-01-21
US10117848B2 (en) 2018-11-06
US20240277652A1 (en) 2024-08-22
EP3689344B1 (en) 2024-06-05
DK3283067T3 (da) 2020-03-30
SI3283067T1 (sl) 2020-07-31
IL254889A0 (en) 2017-12-31
JP2018514527A (ja) 2018-06-07
ZA201706648B (en) 2020-01-29
AU2016249030A1 (en) 2017-10-26
MA46679B1 (fr) 2020-04-30
RU2017134553A3 (lt) 2019-11-13
CN113694019A (zh) 2021-11-26
MD3283067T2 (ro) 2020-05-31
PL3283067T3 (pl) 2020-09-21
US20190269643A1 (en) 2019-09-05
EP3689344A1 (en) 2020-08-05
RU2731918C2 (ru) 2020-09-09
CN107613970A (zh) 2018-01-19
CA2982622C (en) 2023-08-22
EP4428119A3 (en) 2024-11-13
US20180110752A1 (en) 2018-04-26
RS60154B1 (sr) 2020-05-29
PT3689344T (pt) 2024-09-04
EP4428119A2 (en) 2024-09-11
US20220296556A1 (en) 2022-09-22
BR112017021620B1 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
IL284874A (en) Valbenazine salts and polymorphs thereof
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3560924T (lt) Imidazolonilchinolinai ir jų panaudojimas kaip atm kinazės inhibitorių
PT3548033T (pt) Compostos e respectivos métodos de utilização
LT3221306T (lt) Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
LT3205650T (lt) Egfr inhibitorius ir jo gavimas bei taikymas
LT3193611T (lt) Mk2 inhibitoriai ir jų panaudojimas
IL264258B (en) Substituted diazahetero-bicyclic compounds and their use
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
LT3177608T (lt) Proteinkinazės c inhibitoriai ir jų naudojimo būdai
EP3386505A4 (en) AZA-BENZIMIDAZOLINHIBITORS OF PAD4
EP3379139A4 (en) LAMPHOLDER
LT3265126T (lt) Tesofensino ir metoprololio derinio kompozicija
LT3129019T (lt) Artemizinino junginių ir gefirino agonistų medicininis panaudojimas
DK3098281T3 (da) Sammensætning omfattende hfc og hfo
LT3337506T (lt) Deriniai ir jų panaudojimas
LT3347356T (lt) Tricikliniai sulieti piridin-2-ono dariniai ir jų naudojimas kaip brd4 inhibitorių
LT3231793T (lt) Dihidropirimidin-2-ono junginiai ir jų medicininis panaudojimas
EP3107540A4 (en) Polymorphs of lomitapide and its salts
IL264445A (en) Compounds and compositions and uses thereof
LT3247711T (lt) Naujos scy-078 druskos ir polimorfai
EP3417845A4 (en) ALPHA FORMULATION COMPOSITION AND ALPHA YELLOW COMPOSITION
LT3283067T (lt) Trumpo poveikio fenilalkilamino kalcio kanalų blokatoriaus gerai vandenyje tipstančios druskos ir jų panaudojimas
SI3189045T1 (sl) Nove soli nilotiniba in njih polimorfi
EP3402328A4 (en) FISH FALL RUNNER